Valuation: Imunon, Inc.

Market Cap 8.47M 7.44M 6.99M 6.39M 11.94M 812M 12.03M 83.97M 32.55M 414M 31.82M 31.12M 1.34B P/E 2026 *
-0.63x
P/E 2027 * -0.81x
Enterprise Value 8.47M 7.44M 6.99M 6.39M 11.94M 812M 12.03M 83.97M 32.55M 414M 31.82M 31.12M 1.34B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.27%
Yield 2026 *
-
Yield 2027 * -
1 day-2.65%
1 week+5.00%
Current month-9.82%
1 month-10.37%
3 months-18.33%
6 months-48.78%
Current year-61.42%
1 week 1.33
Extreme 1.33
1.59
1 month 1.33
Extreme 1.33
1.75
Current year 1.33
Extreme 1.33
4.2
1 year 1.33
Extreme 1.33
5.55
3 years 1.33
Extreme 1.33
47.61
5 years 1.33
Extreme 1.33
205.43
10 years 1.33
Extreme 1.33
3,506.11
Manager TitleAgeSince
Chief Executive Officer 56 2024-05-12
Director of Finance/CFO 53 2026-06-30
Chief Tech/Sci/R&D Officer 73 2025-02-17
Director TitleAgeSince
Chairman 75 2014-10-06
Director/Board Member 75 2011-07-07
Director/Board Member 76 2015-12-14
Date Insider Type Main position Quantity % Market Cap. Importance
9/11/26 Free

Chief Executive Officer

5,504 0.2183%
9/11/26 Free

Chairman

5,824 0.2310%
9/11/26 Free

Chief Technology Officer

4,211 0.1670%
Change 5-day change 1-year change 3-year change Capi.($)
-2.65%+5.00%-71.46%-89.27% 8.47M
+0.06%+7.20%+54.04%+111.13% 74.27B
-2.29%-2.68%+32.41%+75.07% 61.21B
+0.28%+7.27%+31.74%+23.80% 27.55B
-2.05%-1.32%-18.40%+352.20% 26.38B
-2.39%+1.83%-0.26%-5.91% 25.34B
+0.57%+6.60%+26.25%-9.37% 20.84B
-1.47%+4.46%-8.09%+513.33% 14.94B
+1.29%-2.49%+163.31%+333.06% 15.17B
-2.44%-0.30%+43.33%+164.11% 14.41B
Average -1.11%+2.48%+25.29%+146.82% 28.01B
Weighted average by Cap. -0.96%+2.31%+35.37%+134.01%

Financials

2026 *2027 *
Net sales - -
Net income -14.47M -12.7M -11.94M -10.91M -20.39M -1.39B -20.54M -143M -55.58M -707M -54.33M -53.14M -2.29B -19.34M -16.98M -15.96M -14.59M -27.27M -1.85B -27.47M -192M -74.32M -945M -72.65M -71.05M -3.06B
Net Debt - -
Logo Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
20
Date Price Change Volume
26-09-23 US$1.470 -2.65% 208,254
26-09-22 US$1.510 +5.59% 331,343
26-09-21 US$1.430 +5.15% 117,031
26-09-18 US$1.360 -1.45% 62,791
26-09-17 US$1.380 -2.13% 109,469
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.510USD
Average target price
17.00USD
Spread / Average Target
+1,025.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMNN Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!